Angle has raised £9.6m (net) via a private placing. This supports Angle’s focus on commercialising Parsortix, with the funds being applied to a range of clinical studies to demonstrate utility of the Parsortix system. Additionally, Angle announced that Cancer Research UK Manchester Institute is adopting Parsortix for routine research use, which will provide recurring sales. FY16 results in July will provide a trading update and more details on the R&D expansion strategy, likel
27 May 2016
Funds for new clinical trials and more sales to KOL
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Funds for new clinical trials and more sales to KOL
ANGLE plc (AGL:LON) | 12.5 0 0.0% | Mkt Cap: 32.6m
- Published:
27 May 2016 -
Author:
Jonas Peciulis -
Pages:
3
Angle has raised £9.6m (net) via a private placing. This supports Angle’s focus on commercialising Parsortix, with the funds being applied to a range of clinical studies to demonstrate utility of the Parsortix system. Additionally, Angle announced that Cancer Research UK Manchester Institute is adopting Parsortix for routine research use, which will provide recurring sales. FY16 results in July will provide a trading update and more details on the R&D expansion strategy, likel